Across industries, senior leaders are navigating a workforce challenge created by increasingly specialized business demands. Technology, finance, manufacturing, and healthcare can require highly specific expertise for initiatives that may last months or cover a particular stage of a larger transformation. Traditional talent structures, built around permanent roles and fixed responsibilities, can make it challenging to match specialized capabilities with rapidly changing priorities.
The tension becomes particularly visible when a new regulatory requirement, technology, product milestone, or strategic initiative creates an immediate need for expertise. Executive hiring can take months, while the need itself may have a much shorter timeframe. This has helped increase interest in fractional leadership, where experienced executives provide specialized capabilities for defined periods or specific business needs.
Pharmaceuticals offer a particularly useful example because scientific complexity, regulation, and stakeholder expectations continue to evolve at the same time. Within that environment, Medical Affairs demonstrates how an organization may require highly specialized leadership at certain points in a product’s development without necessarily needing those same capabilities throughout the entire lifecycle.
Medical Affairs remains less familiar to many people outside the pharmaceutical sector than R&D or commercial functions. Its responsibilities, however, occupy an important scientific role within a pharmaceutical organization. Medical Affairs professionals facilitate scientific exchange with healthcare professionals, interpret and communicate evidence, support evidence-generation activities, and help connect emerging scientific knowledge with the needs of clinicians and patients. The distinction between scientific exchange and promotional activity also remains important in a highly regulated environment, where pharmaceutical communications must comply with applicable FDA requirements.
Michelle Chernock, PhD, founder of Leaders in Medical Affairs, a Medical Affairs consulting firm serving pharmaceutical, biotechnology, and medical device organizations, has more than two decades of experience working across startup and global pharmaceutical environments. Her perspective highlights a recurring leadership challenge. “Organizations can have an established Medical Affairs function while still encountering a specialized capability gap at a particular point in development, launch, or therapeutic-area expansion,” she notes.
That gap can arise because Medical Affairs covers a broad range of disciplines. Teams may need expertise in compliance, physician communications, evidence interpretation and generation, external expert engagement, medical strategy, or therapeutic-area knowledge. A team member with deep experience in one phase of development may face a different set of demands in another. Dr. Chernock’s experience suggests that the question for executives increasingly becomes how to access the right expertise for a specific business need and timeframe.
The broader scientific environment adds further weight to that question. McKinsey’s research on Medical Affairs describes an industry with expanding therapeutic options, increasingly sophisticated data, and rapidly developing digital and analytical capabilities. Its report notes that healthcare practitioners and patients had access to 75% more assets per indication than a decade earlier, contributing to the volume of scientific information clinicians must navigate. McKinsey also identifies capability gaps, budget constraints, organizational alignment, and competing priorities as factors influencing the evolution of Medical Affairs.
For Dr. Chernock, this environment creates a practical case for experienced fractional expertise. “A company may require senior leadership for a launch, temporary leave coverage, a therapeutic-area expansion, an unusually demanding workload, or a specific capability that has yet to be developed internally,” she explains. “An experienced professional can contribute to a defined need while the organization determines its longer-term structure in such circumstances.”
This model also reflects a broader shift in executive careers. Dr. Chernock points to similar dynamics in technology, where shorter business and product cycles can create demand for specific executive capabilities over six to 24 months. Senior professionals with decades of experience may increasingly choose portfolio careers that allow them to apply specialized knowledge across organizations and defined periods.
The distinction between fractional leadership and conventional consulting is important here. Fractional executives can become part of the leadership structure for a specific period or mandate, contributing expertise and accountability alongside internal teams. This arrangement can give organizations access to senior-level knowledge when a permanent position may exceed the actual duration or scope of the need.
“Executives can begin identifying a Medical Affairs capability gap by asking several questions,” Dr. Chernock states. “Does the organization have the expertise required for its current development stage? Is an upcoming launch creating a temporary increase in complexity? Does a therapeutic expansion require knowledge that the existing team has limited exposure to? Could a short-term leadership requirement benefit from someone who has already navigated a comparable situation?”
These questions point to a larger evolution in how organizations may think about talent. As scientific fields become more specialized and business cycles accelerate, executive capacity can increasingly be assembled around the work itself, its timing, and the expertise required. McKinsey’s vision for Medical Affairs similarly anticipates broader skill sets, greater use of analytics and digital capabilities, and organizational models that can adapt to changing priorities.
For pharmaceutical leaders, the lesson extends beyond staffing. Medical Affairs sits within a business environment where scientific credibility, responsible communication, evidence generation, and stakeholder needs intersect with major organizational decisions. Access to the right expertise at the right stage can therefore become an important leadership consideration.
Across industries, the emerging question may be less about maintaining a fixed executive architecture and more about ensuring that specialized knowledge is available when the business requires it. Fractional leadership represents one response to that shift, giving organizations another way to connect experienced expertise with periods of concentrated need.
